Projects per year
Personal profile
Education
- 1982 Taipei Medical College, M.D.
Research Interests
- Hepatitis
- Hepatocellular Carcinoma
- Virology
Experience
- 1990/8~1993/7 Instructor of Medicine, Medical College, National Cheng Kung University (NCKU)
- 1993/8~1996/7 Associate Professor, Medical College, National Cheng Kung University (NCKU)
- 1996/8~present Professor of Medicine, Medical College, National Cheng Kung University (NCKU)
- 1998/8~2000/7 Secretary of Medical Affairs, National Cheng Kung University Hospital (NCKUH)
- 2000/8~2002/7 Director, Department of Clinical Medicine, National Cheng Kung University Hospital (NCKUH)
- 2000/8~2004/7 Director, Institute of Molecular Medicine, Medical College, National Cheng Kung University (NCKU)
- 2000/8~2004/7 Chief, Division of Gastroenterology, National Cheng Kung University Hospital (NCKUH)
- 2003~present Director, Biotechnologic Center of Hepatology, Research and Services Headquarter of National Cheng Kung University
- 2006~present Distinguished Professor of Internal Medicine, Medical College, NCKU
- 2013/8~2017/7 Associate Director, Medical College, National Cheng Kung University Hospital (NCKUH)
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Ting-Tsung Chang is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 40 Finished
-
Agalactosyl IgG induces liver fibrogenesis via Fc gamma receptor 3a on human hepatic stellate cells
Ho, C. H., Chang, T. T., Lin, H. C. & Wang, S. F., 2024 Aug, In: Journal of Pathology. 263, 4-5, p. 508-519 12 p.Research output: Contribution to journal › Article › peer-review
1 Citation (Scopus) -
Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines (Hepatology International, (2021), 15, 6, (1421-1430), 10.1007/s12072-021-10263-x)
Teng, W., Chang, TT., Yang, HI., Peng, CY., Su, CW., Su, TH., Hu, TH., Yu, ML., Yang, HC. & Wu, JC., 2024 Jun, In: Hepatology International. 18, 3, p. 1066 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
Hou, J., Gane, E., Balabanska, R., Zhang, W., Zhang, J., Lim, T. H., Xie, Q., Yeh, C. T., Yang, S. S., Liang, X., Komolmit, P., Leerapun, A., Xue, Z., Chen, E., Zhang, Y., Xie, Q., Chang, T. T., Hu, T. H., Lim, S. G., Chuang, W. L., & 6 others, 2024 Apr, In: Clinical and molecular hepatology. 30, 2, p. 191-205 15 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Citations (Scopus) -
Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan
Wu, J. S., Hong, T. C., Wu, H. T., Lin, Y. J., Chang, T. T., Wang, C. T., Liu, W-C., Hsieh, M. T., Wu, I. C., Chen, P. J., Chen, C. Y., Lin, S. H., Chuang, C. H., Han, M. Z., Chen, H. P., Tsai, H. M. & Kuo, H. Y., 2023 Apr 29, In: Journal of Gastrointestinal Oncology. 14, 2, p. 849-862 14 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Citations (Scopus) -
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
LEAP-002 Investigators, 2023 Dec, In: The Lancet Oncology. 24, 12, p. 1399-1410 12 p.Research output: Contribution to journal › Article › peer-review
Open Access102 Citations (Scopus)